SpringWorks Therapeutics has achieved complete patient enrolment in a Phase II clinical trial of nirogacestat to treat recurrent ovarian granulosa cell tumours (OvGCT).

The open-label, single-arm, multi-centre study will assess the safety, tolerability, efficacy, and pharmacokinetics of nirogacestat as a single agent in patients with recurrent OvGCT.

It enrolled nearly 40 patients who had previously received one or more lines of systemic therapy. They will receive 150mg of nirogacestat two times a day.

The objective response rate as measured by Response Evaluation Criteria in Solid Tumours (RECIST 1.1) is the primary endpoint of the study.

Secondary endpoints include safety, tolerability, quality of life assessments, progression-free survival, overall survival as well as duration of response.

SpringWorks CEO Saqib Islam said: “While early-stage OvGCT can be managed with surgery, nearly half of the patients experience post-surgical recurrence, and once these tumours recur, there are limited treatment options and no FDA-approved therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are very pleased to have fully enrolled on this trial well ahead of our projections, which we believe is a testament to the high unmet need that remains for patients living with OvGCT who are in need of a rational, targeted, oral therapy to treat their tumours.

“We look forward to continuing to work closely with our investigators and to reporting initial data from this study next year.”

Nirogacestat is an oral, selective, small-molecule gamma-secretase inhibitor that is currently in Phase III clinical development for desmoid tumours.

In addition to OvGCT, SpringWorks is evaluating nirogacestat for multiple myeloma.